Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke
Group Managing Director, Kate Quirke
Source: Alcidion Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) has signed two contracts with Murrumbidgee Local Health District (LHD) to keep using Alcidion’s Miya Precision platform and Miya MEMRe
  • The total combined contract value is $686,000 and runs for a period of 12 months
  • Once deployed, a COVID-19 monitoring capability will be integrated with Miya Precision to assess COVID-19 positive and at-risk patients
  • Additionally, Miya MEMRe will be rolled out to up to 200 clinicians, which is set to reduce the risk of infection from shared devices
  • Company shares are up 3.33 per cent and are trading for 15.5 cents each

Alcidion Group (ALC) has signed two contracts with Murrumbidgee Local Health District (LHD) for continued use of Alcidion’s Miya Precision platform and Miya MEMRe.

In April, Murrumbidgee LHD chose to use Miya Precision for 12 months, starting from January 1. The two contracts have a combined value of $686,000 and are intended to be used at the Wagga Wagga Base Hospital.

Miya Precision provides artificial intelligence-based predictive analysis, clinical support and mobile alerts in an easy-to-use dashboard.

Once deployed, a COVID-19 monitoring capability will be incorporated into Miya Precision to monitor COVID-19 positive and at-risk patients both in-hospital and remotely.

Miya MEMRe will also be rolled out to up to 200 clinicians, which is set to reduce the risk of infection from using shared devices.

Miya MEMRe is a mobile EMR solution which provides real-time and easy access to critical test results and risk indicators to improve clinical decision-making.

“We are delighted that Murrumbidgee LHD has elected to use Miya Precision and MEMRe,” Alcidion Managing Director Kate Quirke said.

“Furthermore, we are pleased to work with the team at Murrumbidgee LHD to further develop the COVID-19 monitoring solution to meet their needs as they utilise vital resources to manage the impact of this ongoing situation,” Kate added.

Company shares are up 3.33 per cent and are trading for 15.5 cents each at 1:01 pm AEST.

ALC by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…